SCYNEXIS (Nasdaq:SCYX) - Stock Price, News & Analysis

SCYX Stock Overview

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States.

About the company

SCYX fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 96.7% below our estimate of its fair value

Became profitable this year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 377.4%

Risk Analysis

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($54M)

SCYNEXIS, Inc. Competitors

Amylyx Pharmaceuticals

NasdaqGS:AMLX

US$134.2m

Earth Science Tech

OTCPK:ETST

US$20.1m

Endexx

OTCPK:EDXC

US$11.0m

Elite Pharmaceuticals

OTCPK:ELTP

US$135.9m

Price History & Performance

Summary of all time highs, changes and price drops for SCYNEXIS
Historical stock prices
Current Share Price	US$1.44
52 Week High	US$3.87
52 Week Low	US$1.35
Beta	1.57
1 Month Change	3.60%
3 Month Change	-21.53%
1 Year Change	-49.30%
3 Year Change	-80.38%
5 Year Change	-90.77%
Change since IPO	-98.40%

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Recent updates

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Apr 13

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Mar 15

Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like

Feb 01

Cantor initiates with Overweight rating for Scynexis and Ardelyx on potential drug approval

Jan 06

Shareholder Returns

	SCYX	US Pharmaceuticals	US Market
7D	2.1%	-1.5%	-3.2%
1Y	-49.3%	9.7%	19.3%

Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.

Return vs Market: SCYX underperformed the US Market which returned 19.3% over the past year.

Price Volatility

Is SCYX's price volatile compared to industry and market?
SCYX volatility
SCYX Average Weekly Movement	9.5%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Stable Share Price: SCYX's share price has been volatile over the past 3 months.

Volatility Over Time: SCYX's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	29	David Angulo	www.scynexis.com

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.

SCYNEXIS, Inc. Fundamentals Summary

How do SCYNEXIS's earnings and revenue compare to its market cap?
SCYX fundamental statistics
Market cap	US$54.37m
Earnings (TTM)	US$67.04m
Revenue (TTM)	US$140.14m

0.8x

P/E Ratio

0.4x

P/S Ratio

Is SCYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCYX income statement (TTM)
Revenue	US$140.14m
Cost of Revenue	US$15.62m
Gross Profit	US$124.52m
Other Expenses	US$57.48m
Earnings	US$67.04m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	1.78
Gross Margin	88.85%
Net Profit Margin	47.84%
Debt/Equity Ratio	16.4%

How did SCYX perform over the long term?

See historical performance and comparison

SCYX Stock Overview

Rewards

Risk Analysis

SCYNEXIS, Inc. Competitors

NasdaqGS:AMLX

US$134.2m

OTCPK:ETST

US$20.1m

OTCPK:EDXC

US$11.0m

OTCPK:ELTP

US$135.9m

Price History & Performance

Recent News & Updates

Consensus estimates of losses per share improve by 12%

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Consensus revenue estimates fall by 59%

Scynexis: Update Following Restructuring Of GSK Deal

Full year 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Consensus estimates of losses per share improve by 12%

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Consensus revenue estimates fall by 59%

Scynexis: Update Following Restructuring Of GSK Deal

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Price target decreased by 12% to US$7.13

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Price target decreased by 9.6% to US$10.30

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.5% to US$11.40

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Consensus revenue estimates fall by 35%

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$15.00

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$18.17

SCYNEXIS Q2 2022 Earnings Preview

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

SCYNEXIS gains after favorable data for antifungal agent in new indication

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

Consensus forecasts updated

Price target decreased to US$21.25

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially